As observed in our cohort, lymphopenia secondary to anti-CD20 therapy tends to be mild, predominantly grade 1 or 2, with severe lymphopenia (grade 3 or higher) observed in less than 2% of cases (1, 24, 25). Here, MS4A1 is linked to lymphopenia.